May 01, 2005
By Pharmaceutical Executive Editors

Cover Story Pharma's Top 50: Our 6th Annual Report

Nicole Gray

Contributing Writer

This year's list of the top 50-ranked pharma companies includes movers, mainstays, mergers, and more.



Ad Stars

Joanna Breitstein

Senior Editor

A new Pharm Exec feature: Meet the teams behind some of the top pharma ad campaigns of 2004.


Eisai's New Leadership

Joanna Breitstein

Senior Writer

US president and COO Lonnel Coats, and chairman and CEO Hajime Shimizu, talk about their first year at the helm of Eisai.

Clinical Trials

Site Selection

Richard Gliklich, MD


In the fast-growing world of post-approval studies, competition for research sites is heating up. Here's how to play the game.


Elephant or Specialist?

Eric Felker

Apollo Consulting Group

Medicare wants to create new market forces to drive down costs. How should you respond? First you need to know what you are.

Call Centers

Beyond the Call

Stan Zehner and Beth Ann Pelegan

RWD Technologies

Sure, an integrated call center system can make phone operators' jobs easier. But there's a much better reason to use one.

Cutting Edge

It's All About Immunity

L.J. Sellers

Contributing Writer

After 9/11, San Diego-based Hollis-Eden discovered a new mission: developing an FDA-approved treatment for acute radiation sickness.

Special Report: Spend Trends

Changing Lanes

Diane West

Contributing Writer

Analysts predict that the booming DTC advertising market is about to shift from branded campaigns to disease-awareness efforts.

Leading Indicators News Giuliani's research group pokes holes in drug importation plans " WHO calls for international treaty to combat counterfeiting of drugs " FDA bans inhalers that use chlorofluorocarbon propellants " Pfizer gets warned about Zyrtec ads " Part B: the new Part D

Data Americans fail compliance test " Potential problems with Part B price controls " Mental health meds are in high demand

Thought Leaders Lisa Drakeman, Genmab's CEO, on the art of biotech dealmaking.

Washington Report Some think recent withdrawal actions signal a more risk-averse stance at FDA; cynics say it's just another swing of the regulatory pendulum.

Jill Wechsler

Global Report Government officials in the UK are calling for tougher regulations of pharma.

Sarah Houlton

Leadership Two perspectives on achieving work/life balance.

Sander Flaum Flaum Partners

Jonathon Flaum WriteMind Communications

Legal ForumPatent rulings have limited the use of costly research tools. Researchers are coming up with answers.

lorem ipsum